Literature DB >> 435799

Treatment of ulcerative colitis with thalidomide.

M F Waters, A B Laing, A Ambikapathy, J E Lennard-Jones.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 435799      PMCID： PMC1598435          DOI： 10.1136/bmj.1.6166.792

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


× No keyword cloud information.
  3 in total

1.  An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum.

Authors:  M F Waters
Journal:  Lepr Rev       Date:  1971-03       Impact factor: 0.537

2.  Circulating immune complexes in inflammatory bowel disease.

Authors:  D P Jewell; I C MacLennan
Journal:  Clin Exp Immunol       Date:  1973-06       Impact factor: 4.330

3.  Further observation with thalidomide in lepra reactions.

Authors:  J Sheskin
Journal:  Lepr Rev       Date:  1965-10       Impact factor: 0.537
  3 in total
  8 in total

Review 1.  Immunomodulation by thalidomide and thalidomide analogues.

Authors:  L G Corral; G Kaplan
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Thalidomide--the way forward.

Authors:  J M Gardner-Medwin; R J Powell
Journal:  Postgrad Med J       Date:  1994-12       Impact factor: 2.401

3.  Effects of thalidomide on the generation of oxygen intermediates by zymosan-stimulated normal polymorphonuclear leukocytes.

Authors:  Y Miyachi; M Ozaki; K Uchida; Y Niwa
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

Review 4.  Thalidomide in gastrointestinal disorders.

Authors:  A Bousvaros; B Mueller
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Thalidomide in human immunodeficiency virus (HIV) patients. A review of safety considerations.

Authors:  V Günzler
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

Review 6.  Thalidomide and its derivatives: emerging from the wilderness.

Authors:  J N Gordon; P M Goggin
Journal:  Postgrad Med J       Date:  2003-03       Impact factor: 2.401

7.  Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset.

Authors:  P A Haslett; L G Corral; M Albert; G Kaplan
Journal:  J Exp Med       Date:  1998-06-01       Impact factor: 14.307

8.  Thalidomide results in diminished ovarian reserve in reproductive age female IBD patients.

Authors:  Xiang Peng; Min Zhi; Ming Wei; Ting-Ting Li; Min Zhang; Yuan-Qi Zhang; Huan He; Mingli Su; Wei Wang; Jun-Rong Chen; Jian Tang; Xiang Gao; Pin-Jin Hu; Xiao-Yan Liang
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.